ElectroPhysiology Frontiers

ElectroPhysiology Frontiers is a MedTech company actively developing innovative, easy-to-use "single-shot" catheter ablation systems to provide more durable and long-lasting ablations while reducing the recurrence rate of atrial fibrillation (AFib) after pulmonary vein isolation (PVI). Founded by TechWald Holding SpA in 2019, ElectroPhysiology Frontiers later received additional investments from Indaco Venture Partners SGR and Nocturnal Product Development LLC. Since beginning operations in 2019, prototypes have been developed and preclinical testing is currently underway.